ChromaDex Corporation (CDXC)
undefined
undefined%
At close: undefined
6.10
-0.16%
After-hours Dec 13, 2024, 07:07 PM EST

Company Description

ChromaDex Corporation operates as a bioscience company focusing on healthy aging.

The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services.

It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.

The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function.

It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries.

The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States.

ChromaDex Corporation is headquartered in Los Angeles, California.

ChromaDex Corporation
ChromaDex Corporation logo
Country United States
IPO Date Jun 25, 2008
Industry Biotechnology
Sector Healthcare
Employees 106
CEO Robert N. Fried

Contact Details

Address:
10900 Wilshire Boulevard
Los Angeles, California
United States
Website https://www.chromadex.com

Stock Details

Ticker Symbol CDXC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001386570
CUSIP Number 171077407
ISIN Number US1710774076
Employer ID 26-2940963
SIC Code 2833

Key Executives

Name Position
Robert N. Fried Chief Executive Officer & Director
Michiko Kelley Chief Marketing Officer
Ozan Pamir C.F.A. Chief Financial Officer & Principal Accounting Officer
Alex Worsham Vice President of Global Marketing & Communications
Carlos Lopez Senior Vice President & General Counsel
Chu Yan Managing Director of Asia Pacific
Dr. Andrew Shao Ph.D. Senior Vice President of Global Regulatory & Scientific Affairs
Frank Louis Jaksch Jr. Co-Founder & Chairman
James Lee Controller
Kendall Knysch Head of Media Relations & Partnerships

Latest SEC Filings

Date Type Title
Dec 04, 2024 8-K Current Report
Nov 25, 2024 4 Filing
Nov 21, 2024 424B3 Filing
Nov 21, 2024 8-K Current Report
Nov 08, 2024 3 Filing
Oct 31, 2024 8-K Current Report
Oct 31, 2024 10-Q Quarterly Report
Oct 23, 2024 4 Filing
Oct 23, 2024 3 Filing
Oct 11, 2024 8-K Current Report